CSPC Pharmaceutical Group Announces Acceptance of Sirolimus for Injection (Albumin-Bound) NDA by NMPA, with Breakthrough Therapy and Priority Review Status
Key Points for Investors:
- New Drug Application (NDA) Accepted: The National Medical Products Administration (NMPA) of China has officially accepted the NDA for CSPC Pharmaceutical Group’s Sirolimus for Injection (Albumin-Bound), a drug independently developed by the company.
- Breakthrough Therapy & Priority Review: The product has been included in the Breakthrough Therapy Drug Program and granted Priority Review status. This could significantly accelerate the approval process and bring the product to market faster, which is typically viewed as highly price-sensitive and potentially share price moving.
- Novel Mechanism & Indication: Sirolimus for Injection is a macrolide antibiotic immunosuppressant and acts as a highly selective mTOR inhibitor. Its proposed indication is for unresectable locally advanced or metastatic malignant perivascular epithelioid cell tumour (PEComa), a rare and difficult-to-treat cancer.
- Clinical Results: The NDA is primarily based on a pivotal Phase Ib/III clinical study in histologically confirmed, unresectable, locally advanced or metastatic malignant PEComa patients who had not previously received mTOR inhibitor therapy. The Phase III trial met its predefined primary endpoint, demonstrating statistically significant and clinically meaningful efficacy advantages over conventional therapies, including rapid and deep tumour responses.
- Potential New Treatment Standard: Given the lack of a unified standard treatment regimen for malignant PEComa, CSPC’s product may establish a new standard of care and support the development of a standardized treatment framework in this area.
- Safety Profile: The drug demonstrated a favorable overall safety profile, with manageable adverse reactions and a wide safety margin, making it a core therapeutic option for this rare tumour type.
- First-in-China Innovation: This is the first intravenous sirolimus formulation approved for clinical research in China, highlighting CSPC’s innovative leadership.
- Pipeline Expansion: CSPC is advancing a pivotal Phase III clinical trial of the product in combination with fulvestrant for HR+/HER2- breast cancer and is also exploring its use in monotherapy and combination regimens across various solid tumours.
Shareholder Considerations & Potential Price Sensitivity:
- The acceptance of the NDA, Priority Review, and Breakthrough Therapy status are major regulatory milestones that may positively affect market perception and share value, especially given the potential for accelerated commercialization.
- The clinical trial results showing significant efficacy and safety for a rare cancer with unmet needs further strengthen CSPC’s market position and future revenue prospects.
- Expansion of indications and combination trials in breast cancer and other solid tumours could unlock additional value and growth opportunities for the company.
Board Update: The announcement was made by Chairman Mr. Cai Dong Chen on 27 July 2026. The Board comprises a mix of executive and independent non-executive directors, reflecting robust corporate governance.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making any investment decisions. CSPC Pharmaceutical Group’s share price may be affected by regulatory outcomes, clinical trial results, and other external factors.
石藥集團公佈白蛋白結合注射用西羅莫司新藥申請獲中國藥監局受理，納入突破性療法及優先審評
投資者重點：
- 新藥申請獲受理：中國國家藥品監督管理局（NMPA）正式受理石藥集團自主研發的白蛋白結合注射用西羅莫司新藥申請。
- 突破性療法及優先審評：該產品被納入突破性療法藥物計劃並獲得優先審評資格，有望大幅加快審批進程並提前上市，對股價具明顯敏感性。
- 創新機制及適應症：西羅莫司注射劑屬大環內酯類抗生素免疫抑制劑，是高度選擇性mTOR抑制劑，擬用於不可切除的局部晚期或轉移性惡性血管周細胞瘤（PEComa），屬罕見難治癌症。
- 臨床數據：申請資料主要來自關鍵性Phase Ib/III臨床研究，入組未曾接受mTOR抑制劑治療的惡性PEComa患者。第三期臨床達到預設主要終點，療效較傳統治療明顯優勢，腫瘤反應迅速且深度顯著。
- 有望成為新標準：鑒於現時PEComa尚無統一標準治療方案，石藥產品有望成為新標準並推動行業規範化。
- 安全性優勢：產品整體安全性良好，副作用可控，安全界限寬，適合用於此罕見腫瘤類型。
- 中國首創：這是中國首個獲批臨床研究的靜脈注射西羅莫司製劑，彰顯石藥創新領導力。
- 管線拓展：集團正推進與氟維司坦聯合治療HR+/HER2-乳腺癌的三期臨床，同時探索單藥及多種聯合方案於其他實體瘤的療效與安全性。
股東須知及股價敏感事項：
- 新藥申請獲受理、優先審評及突破性療法資格屬重大監管里程碑，或正面影響市場預期及股價，特別是有望加快產品商業化。
- 臨床數據展現顯著療效和安全性，對罕見癌症市場具領先優勢，增強未來收入預期。
- 適應症拓展及乳腺癌等聯合療法臨床進展，將帶來額外價值與增長機會。
董事會更新：此公告由董事長蔡東辰於2026年7月27日發布，董事會成員包括多位執行及獨立非執行董事，體現公司治理多元。
免責聲明：本文僅作資訊參考，不構成任何投資建議。投資者應自行研究或諮詢專業金融顧問後決定。石藥集團股價或受監管結果、臨床數據及其他外部因素影響。
